Is there a patent protecting Wegovy in Canada?
Wegovy (semaglutide) has patent protection in Canada that can affect when generic or biosimilar versions are allowed to enter the Canadian market. In Canada, patent coverage for medicines is typically tied to Health Canada’s drug submission and the patent listings that come with it under the regulatory patent framework, which can include patents covering the active ingredient, formulations, and/or methods of use.
Specific details (which patents, their numbers, and their end dates) depend on the exact Canadian patent listings for the Wegovy product.
When does Wegovy patent protection expire in Canada?
The “expiration date” depends on the individual patent(s) listed for Wegovy in Canada, since different patents can expire at different times. After the last relevant patent listed for the product expires (or is otherwise dealt with), manufacturers may be able to pursue approval and launch of competing products, subject to regulatory requirements and any litigation.
To find the accurate expiry timing for the Canadian situation, you would check the specific patent listings for Wegovy in Health Canada’s drug patent-related records (the patents are the controlling factor, not the general timeline for semaglutide).
Can a generic or biosimilar enter Canada before patent expiry?
It is possible for competing manufacturers to enter later than the approval date of a generic/biosimilar because Canadian patent linkage rules can delay market entry while patents are active or while disputes are resolved.
For semaglutide products, the practical question is whether a competitor is seeking approval for a product that can rely on regulatory pathways while still facing active patent protections listed for Wegovy.
What does the Canada “patent linkage” system mean for Wegovy?
Canada uses a system where patent listings tied to a drug submission can trigger procedures that delay market entry of competing versions for a period, unless the patent dispute is resolved in a way that clears the way for earlier entry.
So even if a company gets regulatory clearance, listed patents can still block or delay commercialization in Canada during the dispute and/or until patent protections run out.
Why do different semaglutide brands (and same molecule competitors) still matter for patents?
Even when products share the same active ingredient (semaglutide), patents can be different by:
- specific formulation or dosing device/strength,
- specific method-of-use claims,
- and which product the patents were listed against.
That means the timing for Wegovy in Canada may not match timelines for other semaglutide products (or for Ozempic-related listings), even if the molecule is the same.
How to get the exact Canadian patent numbers and dates for Wegovy
To answer the question precisely for Canada, you need the Wegovy entry in Health Canada’s drug patent information system and then review:
- each listed patent,
- the patent expiry date for each,
- and whether any patents were narrowed, invalidated, or otherwise resolved through disputes.
If you share which year/version of Wegovy you mean (or the strength), I can help you map what to look for in the Canadian listings and how to interpret which patent expiry controls market entry.
Sources
I don’t have the Canadian patent-listing records for Wegovy available in the information provided here, so I can’t cite specific patent numbers or expiry dates without a link or the exact Health Canada listing you want to use.